Loratadine, tablets 10 mg 10 pcs

Pharmacodynamics

Loratadine is a tricyclic compound with pronounced antihistamine action and is a selective blocker of peripheral H1-histamine receptors. It has a rapid and prolonged antiallergic effect. Onset of action is within 30 minutes after ingestion. Antihistamine effect reaches its maximum after 8-12 hours from the beginning of action and lasts for more than 24 hours.

Pharmacokinetics

Loratadine is quickly and well absorbed in the gastrointestinal tract. Time to reach maximum concentration (Tmax) of loratadine in blood plasma is 1-1.5 hours, and its active metabolite desloratadine – 1.5-3.7 hours. Food intake increases Tmax of loratadine and desloratadine by approximately 1 hour, but has no effect on the effectiveness of the drug.

Indications

seasonal (hay fever) and year-round allergic rhinitis, allergic conjunctivitis – elimination of symptoms associated with these diseases: sneezing, itching of the nasal mucosa, rhinorrhea, burning sensation and itching in the eyes, lacrimation;
skin diseases of allergic origin (including chronic idiopathic urticaria);
allergic reactions to insect bites;
pseudoallergic reactions.

Pharmacological effect

Pharmacodynamics

Loratadine is a tricyclic compound with a pronounced antihistamine effect and is a selective blocker of peripheral H1-histamine receptors. Has a quick and long-lasting antiallergic effect. Onset of action is within 30 minutes after ingestion. The antihistamine effect reaches its maximum after 8-12 hours from the onset of action and lasts more than 24 hours.

Pharmacokinetics

Loratadine is quickly and well absorbed from the gastrointestinal tract. The time to reach the maximum concentration (Tmax) of loratadine in the blood plasma is 1-1.5 hours, and its active metabolite desloratadine is 1.5-3.7 hours. Eating increases the Tmax of loratadine and desloratadine by approximately 1 hour, but does not affect the effectiveness of the drug.

Active ingredient

Loratadine

Composition

Active substance:

Loratadine -10.0 mg.

Excipient:

lactose monohydrate – 71.3 mg

corn starch – 18.0 mg

magnesium stearate – 0.7 mg

Contraindications

Hypersensitivity to loratadine and other components of the drug; lactose intolerance, lactase deficiency, glucose-galactose malabsorption syndrome; breastfeeding period; children under 3 years of age and body weight less than 30 kg.

Side Effects

In clinical studies involving children aged 2 to 12 years, headache (2.7%), nervousness (2.3%), and fatigue (1%) were observed more often than in the placebo group (dummies).

In clinical trials in adults, adverse events observed more frequently than with placebo occurred in 2% of patients receiving loratadine. In adults, when using the drug, headache (0.6%), drowsiness (1.2%), increased appetite (0.5%) and insomnia (0.1%) were observed more often than in the placebo group. In addition, there have been very rare post-marketing reports (<1/10,000) of dizziness, fatigue, dry mouth, gastrointestinal disorders (nausea, gastritis), allergic reactions such as rash, anaphylaxis including angioedema, alopecia, liver dysfunction, palpitations, tachycardia and convulsions.

If any of the side effects indicated in the instructions get worse, or you notice any other side effects not listed in the instructions, tell your doctor.

Interaction

Eating does not affect the effectiveness of loratadine.
Loratadine does not potentiate the effect of alcohol on the central nervous system.
When loratadine is taken together with erythromycin, ketoconazole or cimetidine, an increase in the concentration of loratadine and its active metabolite in the blood plasma is observed, but this increase is not clinically significant, including according to ECG data.

Overdose

Symptoms: headache, drowsiness, tachycardia. In case of overdose, consult a doctor immediately.

Treatment: symptomatic and supportive therapy. It is possible to lavage the stomach, take adsorbents (crushed activated carbon with water).

Loratadine is not eliminated by hemodialysis. After emergency care is provided, it is necessary to continue monitoring the patient’s condition.

Manufacturer

Update of PFC JSC, Russia